Spots Global Cancer Trial Database for A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Official Title: PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER
Study ID: NCT00585195
Study Description
Brief Summary: PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California, Irvine Medical Center, Orange, California, United States
University of Colorado Hospital/ Anschutz Cancer Pavilion, Aurora, Colorado, United States
University of Colorado Hospital, Aurora, Colorado, United States
University of Colorado, Aurora, Colorado, United States
University of Chicago, Chicago, Illinois, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Ophthalmic Consultants of Boston Inc., Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana Farber Cancer Center, Boston, Massachusetts, United States
Joslin Beetham Eye Institute, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Kresge Eye Institute, Detroit, Michigan, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center: Breast and Imaging Center, New York, New York, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
UNC Hospitals, Chapel Hill, North Carolina, United States
The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
Ohio State Eye and Ear Institute, Columbus, Ohio, United States
The Ohio State University Martha Morehouse Medical Plaza, Columbus, Ohio, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States
Vanderbilt Eye Institute, Nashville, Tennessee, United States
The University of Vermont Medical Center, Burlington, Vermont, United States
The University of Vermont Cancer Center, Burlington, Vermont, United States
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Aichi cancer center central hospital, Nagoya, Aichi, Japan
Hyogo Cancer Center, Akashi, Hyogo, Japan
Kindai University Hospital, Osakasayama, Osaka, Japan
Seoul National University Hospital, Seoul, , Korea, Republic of
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
